MedDataX Logo

Treatment of Overactive Bladder With Anticholinergic Agents

NCT ID: NCT07046156

Last Updated: 2025-07-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-09-01

Study Completion Date

2026-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate the efficacy and adverse effect incidence of three different anticholinergics (oxybutinin, propiverine, and tolterodine) that are used in children with overactive bladder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transdermal Versus Oral Oxybutynin in Pediatric OAB

NCT07081906

Overactive Bladder (OAB) Drug Delivery Systems Anticholinergic Side Effects +1 more
COMPLETED NA

Comparative Study of the Efficacy of Treatment of Idiopathic Overactive Bladder (OAB) in Children: Oxybutynine vs. Transcutaneous Neurostimulation

NCT07030803

Overactive Bladder (OAB) Transcutaneous Neurostimulation Posterior Tibial Nerve Stimulation
RECRUITING NA

Urinary Biomarkers in Overactive Bladder in Children

NCT02704013

Overactive Bladder
UNKNOWN NA

Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder

NCT00795925

Overactive Bladder
COMPLETED PHASE2

Overactive Bladder Syndrome

NCT05151081

Overactive Bladder Syndrome Enuresis, Nocturnal
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of approximately 150 patients with overactive bladder will be evaluated retrospectively. Clinical and demographic data and voiding diaries of these patients will be evaluated. For this purpose, patients will be divided into mainly three groups according to the anticholinergic agent used.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overactive Bladder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oxybutynin

Patients treated with oxybutynin

Oxybutynin Cl

Intervention Type DRUG

Oxybutynin in a dose of 0.5 mg/kg will be used in the treatment of overactive bladder

Propiverine

Patients treated with propiverine

propiverine

Intervention Type DRUG

Propiverine in a dose of 0.8 mg/kg will be used in the treatment of overactive bladder

Tolterodine

Patients treated with tolterodine

Tolterodine

Intervention Type DRUG

Tolterodine in a dose of 0.1 mg/kg will be used in the treatment of overactive bladder

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxybutynin Cl

Oxybutynin in a dose of 0.5 mg/kg will be used in the treatment of overactive bladder

Intervention Type DRUG

propiverine

Propiverine in a dose of 0.8 mg/kg will be used in the treatment of overactive bladder

Intervention Type DRUG

Tolterodine

Tolterodine in a dose of 0.1 mg/kg will be used in the treatment of overactive bladder

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with overactive bladder
* Patients treated with an anticholinergic

Exclusion Criteria

* Presence of anatomical or neurological problems
* Patients with missing data
Minimum Eligible Age

5 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Furkan Adem Canbaz

Medical doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sancaktepe Sehit Prof dr Ilhan Varank Training and Research Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Ramsay S, Bolduc S. Overactive bladder in children. Can Urol Assoc J. 2017 Jan-Feb;11(1-2Suppl1):S74-S79. doi: 10.5489/cuaj.4337.

Reference Type BACKGROUND
PMID: 28265325 (View on PubMed)

Park SJ, Pai KS, Kim JM, Park K, Kim KS, Song SH, Park S, Kim SO, Ryu DS, Baek M, Lee SD, Lee JW, Im YJ, Han SW, Chung JM, Cho MH, Ha TS, Cho WY, Suh HJ; Korean Children's Continence and Enuresis Society. Efficacy and tolerability of anticholinergics in Korean children with overactive bladder: a multicenter retrospective study. J Korean Med Sci. 2014 Nov;29(11):1550-4. doi: 10.3346/jkms.2014.29.11.1550. Epub 2014 Nov 4.

Reference Type BACKGROUND
PMID: 25408588 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Ivstrh - OAB

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children
NCT02327936 COMPLETED PHASE3
Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
NCT00224016 COMPLETED PHASE4
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
NCT01192568 COMPLETED PHASE4
Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder
NCT00780832 TERMINATED NA
Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder
NCT01539707 COMPLETED PHASE1
Early Oxybutinin Treatment for Boys With Posterior Urethral Valves
NCT04526353 UNKNOWN PHASE2
Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence
NCT00603343 COMPLETED PHASE3
Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome
NCT02024945 COMPLETED
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
NCT00350636 COMPLETED PHASE3
Study of ONO-8539 in Patients With Overactive Bladder
NCT00876421 COMPLETED PHASE2
Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers
NCT00752141 COMPLETED PHASE1
A Study of YM178 in Subjects With Symptoms of Overactive Bladder
NCT01043666 COMPLETED PHASE3
Efficacy of 200 IU OnabotulinumtoxinA in Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment
NCT06408051 COMPLETED
Ability to Awaken in Nonmonosymptomatic Enuresis
NCT02845648 COMPLETED
The Role of Urinary ATP in the Diagnosis, Treatment, and Follow-up of Children with Overactive Bladder
NCT06785558 COMPLETED NA
A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug
NCT01565707 COMPLETED PHASE3
A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076
NCT01655069 COMPLETED PHASE3
Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin
NCT03758235 UNKNOWN PHASE3
PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder
NCT00340704 COMPLETED PHASE2
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
NCT03903094 COMPLETED
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
NCT00507169 COMPLETED PHASE2
A Study to Evaluate the Safety and Efficacy of OROS® Oxybutynin Chloride for the Treatment of Urge Urinary Incontinence
NCT00269724 COMPLETED PHASE3
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
NCT01423838 UNKNOWN PHASE4
Compare Sudden Stopping and Weaning of Anticholinergics in Recurrence of OAB Symptoms
NCT04064619 COMPLETED NA
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
NCT00857896 COMPLETED PHASE2